Duloxetine: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Pharmacopedia: remove contraindications parameter |
MDElliottMD (talk | contribs) Pharmacopedia: add <pharmaInteractions/> |
||
| Line 43: | Line 43: | ||
* '''Anticoagulants / antiplatelets / NSAIDs''' — additive bleeding risk | * '''Anticoagulants / antiplatelets / NSAIDs''' — additive bleeding risk | ||
* '''CYP2D6 substrates''' — duloxetine is a moderate CYP2D6 inhibitor; can elevate levels of metoprolol, propafenone, flecainide, certain TCAs | * '''CYP2D6 substrates''' — duloxetine is a moderate CYP2D6 inhibitor; can elevate levels of metoprolol, propafenone, flecainide, certain TCAs | ||
<pharmaInteractions/> | |||
| pregnancy_details = Category C. Third-trimester use associated with persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome (jitteriness, feeding difficulty, respiratory distress). Risk-benefit decision; if continuation is needed, sertraline is often preferred among SNRIs/SSRIs in pregnancy. Excreted in breast milk in low amounts. | | pregnancy_details = Category C. Third-trimester use associated with persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome (jitteriness, feeding difficulty, respiratory distress). Risk-benefit decision; if continuation is needed, sertraline is often preferred among SNRIs/SSRIs in pregnancy. Excreted in breast milk in low amounts. | ||
| monitoring = * Blood pressure at initiation and dose changes | | monitoring = * Blood pressure at initiation and dose changes | ||